FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome FDA OKs Mepolizumab (Nucala) for Hypereosinophilic Syndrome

Mepolizumab is indicated for adults and children aged 12 years and older with HES for 6 months or longer without an identifiable nonhematologic secondary cause.FDA Approvals
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Hematology-Oncology News Alert Source Type: news